Human Monoclonal Antibodies: On the Menu of Targeted Therapeutics Against COVID-19  

作　　者：Junsen Chen Rui Huang Yiwen Nie Xinyue Wen Ying Wu 

机构地区：[1]State Key Laboratory of Virology,School of Basic Medical Sciences,Wuhan University,Wuhan 430072,China [2]Hubei Province Key Laboratory of Allergy and Immunology,Wuhan 430072,China

出　　处：《Virologica Sinica》2020年第6期713-724,共12页中国病毒学（英文版）

基　　金：supported by Grants from the National Science and Technology Major Project (Grant No.2018ZX10733403)。

摘　　要：Coronavirus disease 2019(COVID-19), reminiscent of the severe acute respiratory syndrome(SARS) outbreak in 2003,has been a tragic disaster to people all over the world. As there is no specific drug for COVID-19, neutralizing antibodies are attracting more and more attention as one of the most effective means to combat the pandemic. Here, we introduced the etiological and serological characteristics of COVID-19, discussed the current stage of development of human monoclonal antibodies against SARS-CoV-2 and summarized the antigenic epitopes in the S glycoprotein, which may deepen the understanding of the profile of immune recognition and response against SARS-CoV-2 and provide insight for the design of effective vaccines and antibody-based therapies.

关 键 词：COVID-19 MABS S glycoprotein EPITOPES 

分 类 号：R392-33[医药卫生—免疫学]